Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å lære mer om endringen i blodnivåene av transtyretin når deltakere med transtyretinamyloidose med kardiomyopati bytter fra tafamidis til akoramidis (ACO-SWITCH)

10. november 2026 oppdatert av: Bayer

En prospektiv, énarms, fase 4-studie for å evaluere forløpet av serum transtyrein (TTR)-nivå med acoramidis hos voksne pasienter med variant eller villtype transtyrein amyloidose med kardiomyopati (ATTR-CM) som tidligere er behandlet med tafamidis

Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this protein breaks down and forms harmful clumps called amyloid. TTR amyloid gets deposited in the heart wall and stops it from pumping blood properly, which may lead to heart failure. The breakage in TTR protein can be age-related (wild-type ATTR-CM), or genetic (variant ATTR-CM).

The study drug, acoramidis, works by attaching itself to the TTR protein, making TTR more stable and less likely to break down and form amyloid (clumps). This helps to slow down the progression of the disease, improve heart function, and increase the TTR levels in the blood. Acoramidis is an approved treatment for wild-type or variant ATTR-CM in Europe and the United States.

Tafamidis is another drug that stabilizes TTR and prevents it from breaking down.

In this study, acoramidis will be studied in participants with ATTR--CM who were previously treated with tafamidis. The main purpose of this study is to assess the change in blood TTR levels after participants are switched from tafamidis to acoramidis. This will be studied to understand if acoramidis causes an increase in blood TTR levels beyond the levels achieved with tafamidis.

For this, the researchers will measure the change in the levels of TTR protein in participants' blood after 6 months of the treatment with acoramidis, or earlier if a participant stops the treatment before reaching that six-month mark.

All participants will continue taking tafamidis during the screening period. In the treatment period of the study, participants will take acoramidis as two tablets twice daily by mouth, for up to 6 months.

At the start of this study, the study doctors will review each participant's medical history and check their overall health. The study doctors will perform electrocardiograms (ECG), and measure blood pressure and heart rate. Researchers will also take blood and urine samples from the participants to measure levels of TTr, NT-proBNP, hs-TnT, hs-CRP, RBP4, eGFR, creatinine, cystatin-C, UACR, and TSH at the start of the study, and at various time points thereafter (during the study) to assess heart, kidney and thyroid function.

There will be a total of 9 study check-ins. Participants will visit the study site twice: at screening and at the end of treatment period. A study nurse will visit the participant's home 6 times, at the start of treatment, Weeks 1, 2, 3 and 4, then again at 3 months. The final check-in will be done by phone.

The study doctors will monitor the health of the participants regularly for any medical problems during follow-up visits. Participants will know the treatment they will receive during the study. Each participant could be in the study for about 8 months.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

50

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Brussels Capital
      • Brussels, Brussels Capital, Belgia, 1070
        • Har ikke rekruttert ennå
        • Hôpital Erasme/Erasmus Ziekenhuis
    • West Flanders
      • Bruges, West Flanders, Belgia, 8000
        • Rekruttering
        • AZ St-Jan Brugge-Oostende A.V.
      • Naples, Italia, 80131
        • Har ikke rekruttert ennå
        • Azienda Ospedaliera Dei Colli_Monaldi - Malattie Rare e Genetiche Cardiovascolari
    • Apulia
      • Lecce, Apulia, Italia, 73100
        • Har ikke rekruttert ennå
        • Ospedale Vito Fazzi Lecce_Cardiologia e UTIC
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, Italia, 40138
        • Rekruttering
        • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola_Cardiologia
    • Lombardy
      • Bergamo, Lombardy, Italia, 24127
        • Rekruttering
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Cardiologia 1
      • Milan, Lombardy, Italia, 20138
        • Rekruttering
        • Centro Cardiologico Monzino S.p.A. - Cardiologia Peri-Operatoria e Imaging Cardiovascolare
      • Pavia, Lombardy, Italia, 27100
        • Har ikke rekruttert ennå
        • Fondazione IRCCS Policlinico San Matteo-SC Medicina Generale 2 - Centro Amiloidosi Sistemiche e Malattie ad Alta Complessità
    • Tuscany
      • Florence, Tuscany, Italia, 50134
        • Rekruttering
        • Careggi University Hospital_cardio intensive care unit
      • Pisa, Tuscany, Italia, 56124
        • Rekruttering
        • Fondazione Toscana Gabriele Monasterio_Pisa - Cardiologia e Medicina Cardiovascolare
      • Siena, Tuscany, Italia, 53100
        • Rekruttering
        • Azienda Ospedaliera Universitaria Senese - cardiologia
    • Veneto
      • Padova, Veneto, Italia, 35128
        • Rekruttering
        • Azienda Ospedale-Università di Padova-UOC Cardiologia
      • Oslo, Norge, 0424
        • Har ikke rekruttert ennå
        • Oslo Universitetssykehus HF, Rikshospitalet
      • Berlin, Tyskland, 10365
        • Tilbaketrukket
        • Sana Klinikum Lichtenberg - Klinik für Innere Medizin II, Schwerpunkt Kardiologie
      • Hamburg, Tyskland, 20246
        • Tilbaketrukket
        • Universitätsklinikum Hamburg Eppendorf (UKE)-Universitären Herz- und Gefäßzentrum Hamburg, Klinik für Kardiologie
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Tyskland, 89081
        • Tilbaketrukket
        • Universitaetsklinikum Ulm | Klinik fuer Innere Medizin II
    • Hesse
      • Darmstadt, Hesse, Tyskland, 64287
        • Har ikke rekruttert ennå
        • KVZ Kardiovaskulaeres Zentrum Darmstadt GmbH
    • Mecklenburg-Vorpommern
      • Greifswald, Mecklenburg-Vorpommern, Tyskland, 17475
        • Tilbaketrukket
        • Universitaetsmedizin Greifswald KöR- Klinik und Poliklinik für Innere Medizin B
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Tyskland, 53127
        • Tilbaketrukket
        • Universitätsklinikum Bonn - Herzzentrum des Universitätsklinikums Bonn
    • Lower Austria
      • Sankt Pölten, Lower Austria, Østerrike, 1210
        • Tilbaketrukket
        • Universitätsklinikum St. Pölten - Lilienfeld - Klinische Abteilung für Innere Medizin 3
    • State of Vienna
      • Vienna, State of Vienna, Østerrike, 3500
        • Har ikke rekruttert ennå
        • Klinik Ottakring - 3. Medizinische Abteilung mit Kardiologie, internistischer Intensivmedizin und Ambulanz
      • Vienna, State of Vienna, Østerrike, 1090
        • Rekruttering
        • Medizinische Universität Wien- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie
      • Vienna, State of Vienna, Østerrike, 1100
        • Rekruttering
        • Klinik Favoriten - 5.Medizinische Abteilung-Kardiologie
    • Styria
      • Vienna, Styria, Østerrike, 1030
        • Rekruttering
        • Medizinische Universität Graz- Klinische Abteilung für Kardiologie
    • Upper Austria
      • Braunau am Inn, Upper Austria, Østerrike, 5280
        • Rekruttering
        • Krankenhaus St. Josef Braunau | Innere Medizin I
    • Vorarlberg
      • Feldkirch, Vorarlberg, Østerrike, 6800
        • Tilbaketrukket
        • VIVIT - Landeskrankenhaus Feldkirch - Innere Medizin I, Kardiologie, Angiologie, Endokrinologie, Diabetologie, Intensivmedizin

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 90 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Participants must be 18 to 90 years of age inclusive, at the time of signing the informed consent.
  • Diagnosis of ATTR-CM; disease defining examination, i.e., Single Photon Emission Computed Tomography (SPECT) or SPECT/Computed Tomography (CT) or biopsy, within 24 months prior to Visit 1 (V1).
  • Participants must currently be treated with tafamidis and have used tafamidis for at least the previous 3 months prior to V1 and have adhered to tafamidis therapy.
  • New York Heart Association (NYHA) class ≤ II at V1.
  • Estimate glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2 at V1.
  • N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) > 300 and ≤ 7000 pg/mL at V1.

Exclusion Criteria:

  • Prior liver or heart transplantation or planned within the next 12 months.
  • Current or planned use of ventricular assist device.
  • Active cancer or other disease that decreases the life expectancy to less than one year.
  • Heart failure due to ischemic heart disease.
  • Myocardial infarction, cardiovascular (CV) surgery, or unstable angina within the last 90 days prior to V1.
  • Confirmed diagnosis of light-chain amyloidosis.
  • Dialysis or severe renal impairment as reflected by Urinary Albumin Creatinine Ratio (UACR) > 300 mg/g at V1.
  • Major surgery within 90 days prior to V1.
  • Recent initiation of Sodium-Glucose-Cotransporter-2 inhibitors (SGLT2i) within 3 months before V1.
  • Initiation of treatment with a diuretic or increase in diuretic dose within 3 months before V1.
  • Treatment with calcium channel blockers (e.g., verapamil, diltiazem) or digitalis.
  • Recent CV hospitalization within 3 months before V1.
  • Known hypersensitivity to acoramidis or to any of the excipients.
  • A condition that, as judged by the investigator, would preclude compliance with the study protocol, such as a history of substance abuse, alcoholism, or a psychiatric condition.
  • Known or suspected liver disorder and bile secretion/flow (cholestasis, also history of it).
  • Abnormal liver function tests at V1, defined as ALT (GPT) or AST (GOT) ≥ 3 x ULN or total bilirubin ≥ 3 x ULN at V1.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Acoramidis

Participants will receive acoramidis 712 mg orally BID

356 mg film-coated tablets.

The recommended dose of acoramidis is 712 mg (two tablets, 356 mg) orally, twice daily, corresponding to a total daily dose of 1424 mg.

Andre navn:
  • BEYONTTRA
  • BAY3684938

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in serum TTR level from baseline to month 6 or premature discontinuation of treatment
Tidsramme: From baseline to month 6 or premature discontinuation of treatment

TTR = Transthyretin

From baseline to month 6 or premature discontinuation of treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall deltakere med TEAEs og alvorlige TEAEs
Tidsramme: Fra første administrering av studiemedisin inntil 30 dager etter siste dose av studiemedisin eller studiens avslutning, avhengig av hva som inntreffer først
Fra første administrering av studiemedisin inntil 30 dager etter siste dose av studiemedisin eller studiens avslutning, avhengig av hva som inntreffer først
Endring fra baseline til måned 6 i kreatinin
Tidsramme: Fra baseline til måned 6
Fra baseline til måned 6
Endring fra baseline til måned 6 i Cystatin C
Tidsramme: Fra baseline til måned 6
Fra baseline til måned 6
Change in serum TTR level from baseline to week 1, 2, 3, 4 and at month 3.
Tidsramme: At baseline, week 1, 2, 3, 4 and at month 3

TTR = Transthyretin

At baseline, week 1, 2, 3, 4 and at month 3
Change from baseline to month 6 of NT-proBNP
Tidsramme: From baseline to month 6

NT-proBNP = N-terminal pro-B-type Natriuretic Peptide

From baseline to month 6
Change from baseline to month 6 of hs-TnT
Tidsramme: From baseline to month 6

hs-TNT = high-sensitivity Troponin T

From baseline to month 6
Change from baseline to month 6 of RBP4
Tidsramme: From baseline to month 6

RBP4 = Retinol Binding Protein 4

From baseline to month 6
Signs of cardiac remodeling from baseline to month 6
Tidsramme: From baseline to month 6

These signs will be measured by echocardiogram

From baseline to month 6
Change from baseline to month 6 in 6MWD
Tidsramme: From baseline to month 6

The 6-Minute Walk distance (6MWD) measures the total distance that a participant could walk in 6 minutes.

From baseline to month 6
Change from baseline to month 6 in the eGFR
Tidsramme: From baseline to month 6

eGFR = estimated glomerular filtration rate

From baseline to month 6
Change from baseline to month 6 in UACR
Tidsramme: From baseline to month 6

UACR = Urinary Albumin Creatinine Ratio

From baseline to month 6
Change from baseline to month 6 in TSH
Tidsramme: From baseline to month 6

TSH = Thyroid Stimulating Hormone

From baseline to month 6
Change from baseline to month 6 in KCCQ-OS score
Tidsramme: From baseline to month 6

The Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) is 23-item questionnaire developed to measure health status and health-related quality of life (QoL) in individuals with heart failure. Items include heart failure symptoms, impact on physical and social functions, and how heart failure impacts QoL.

From baseline to month 6
Change from baseline to month 6 of EQ-5D-5L index score
Tidsramme: From baseline to month 6

The EuroQol-5-Dimension-5-Level (EQ-5D-5L) includes two parts. In the first part, participants are asked to rate their current health state on 5 dimensions (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having five levels of function (1-no problem, 2-slight problem, 3-moderate problem, 4-severe problem, and 5-extreme problem). The second part is a self-rating of current health status on a Visual Analogue Scale (EQ VAS) with endpoints labeled "best imaginable health state" (score of 100) and "worst imaginable health state" (score of 0). The scores from the 5 dimensions are used to calculate the index score.

From baseline to month 6

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. februar 2026

Primær fullføring (Antatt)

17. september 2027

Studiet fullført (Antatt)

17. september 2027

Datoer for studieregistrering

Først innsendt

11. desember 2025

Først innsendt som oppfylte QC-kriteriene

11. desember 2025

Først lagt ut (Faktiske)

22. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

16. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 23026
  • 2025-521831-35-00 (Registeridentifikator: CTIS (EU))
  • 2025 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access.

As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .